Insulin-sensitive Obesity: Prospective and Interventional Studies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Insulin Sensitivity/Resistance
- Sponsor
- Garvan Institute of Medical Research
- Enrollment
- 57
- Locations
- 1
- Primary Endpoint
- Insulin Sensitivity
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
People who are overweight and/or obese are at risk of insulin resistance and type 2 diabetes. However, research has shown that some overweight and/or obese individuals remain insulin-sensitive and metabolically healthy despite their unhealthy body weight.
The investigators hypothesise that overweight and/or obese people who were deemed insulin-sensitive in previous studies will maintain their insulin sensitivity and metabolic health over time. The investigators also hypothesise that the preservation of insulin sensitivity will be accompanied by key metabolic health markers.
Detailed Description
While obesity is a risk factor for metabolic disease, sub cohorts with obesity not complicated by the metabolic syndrome have been described. These so called "metabolically healthy obese" may have reduced risk of type 2 diabetes, cardiovascular disease and all-cause mortality compared with individuals with obesity who present with components of the metabolic syndrome. Longitudinal studies with diabetes and cardiovascular disease risk endpoints reported that individuals with obesity who are metabolically healthy (MHO) held an intermediate health status, such that they were still worse off than the healthy normal-weight individuals. While there have been studies evaluating the stability of the MHO phenotype over time, no study has reported the durability of insulin-sensitivity per se, as measured by the gold-standard hyperinsulinaemic-euglycaemic clamp. In the present study, we aimed to trace the change in insulin resistance/sensitivity, and to uncover predictors of insulin resistance in older age. The secondary aims were to trace the change in body composition, fat distribution and metabolic markers over time in a well-phenotyped cohort studied approximately 5-6 years apart.
Investigators
Dorit Samocha-Bonet
Group leader Clinical Insulin Resistance Group
Garvan Institute of Medical Research
Eligibility Criteria
Inclusion Criteria
- •Participation in two previous studies conducted at the Garvan Institute of Medical Research Clinical Research Facility (described in the other publications 1-3).
- •Willingness to give written informed consent and willingness to participate in the study.
Exclusion Criteria
- •Pregnant and/or lactating women.
Outcomes
Primary Outcomes
Insulin Sensitivity
Time Frame: 6 years
The change in insulin sensitivity (as measured by M-value normalised to insulin from hyperinsulinemic-euglycemic clamp) was determined "Follow-up Value - Baseline Value" /"Time between measurements". There were 2 time points 6 years apart
Secondary Outcomes
- Body Mass Index(6 years)
- Visceral Fat Volume(6 years)
- Diastolic Blood Pressure(6 years)
- Waist Circumference(6 years)
- Body Fat Mass(6 years)
- Fasting Blood Glucose(6 years)
- Body FFM(6 years)
- Systolic Blood Pressure(6 years)
- Fasting Serum Insulin(6 years)